Systemic bevacizumab appears to have significant promise and a low complication profile for the most treatment- resistant and aggressive forms of papillomatosis.
Systemic bevacizumab appears to have significant promise and a low complication profile for the most treatment- resistant and aggressive forms of papillomatosis.